¼¶±ð: Ôº³¤
UID: 85777
¾«»ª: 0
·¢Ìû: 976
ÍþÍû: 15 µã
»ý·Öת»»
ÓÞÓÞ±Ò: 1011 YYB
ÔÚÏß³äÖµ
¹±Ï×Öµ: 0 µã
ÔÚÏßʱ¼ä: 277(Сʱ)
×¢²áʱ¼ä: 2010-02-10
×îºóµÇ¼: 2022-08-22
Â¥Ö÷  ·¢±íÓÚ: 2017-05-09 08:38

 ×¨¼ÒÊӵ㣺¿¹NMDAÊÜÌåÄÔÑ×ÖÎÁÆ·½°¸

¿¹NMDAÊÜÌåÄÔÑ׸ÅÊö

    Ä¿Ç°ÈÏΪ¿¹NMDAÊÜÌåÄÔÑ×ÊÇÒ»ÖÖ¶à½×¶Î¼²²¡£¬µäÐͱíÏÖÊÇÇ°ÇýµÄ·ÇÌØÒìÐÔÁ÷¸ÐÑùÖ¢×´£¬ÒÔ¼°Ëæºó³öÏֵľ«Éñ²¡Ñ§±íÏÖ£¬¶ùͯ»¼Õß³£·¢Õ¹Îª¾ÖÔîÐÔ»òÈ«ÉíÐÔðïÐÔ·¢×÷¡£Ëæ×Å»¼ÕßÒâʶˮƽ³öÏָı估ÆäËûÔ˶¯ÕÏ°­µÄ·¢ÉúÓë·¢Õ¹£¬¾­³£ÐèÒª½«»¼ÕßÊÕÈëICUÖÎÁÆ¡£

    ¿¹NMDAÊÜÌåÄÔÑ׿ÉÄÜÓë12ËêÒÔÉÏÅ®ÐÔ»¼ÕßµÄÖ×Áö£¬ÌرðÊÇÂѳ²»ûÌ¥ÁöÓйء£¸ß´ï67%µÄ»¼ÕßÄÔMRI±íÏÖÕý³££¬ÄÔµçͼÔÚ90%µÄ»¼ÕßÖÐÊÇÒì³£µÄ£¬µ«ÕâЩ·¢ÏÖΪ·ÇÌØÒìÐԸı䡣Õï¶ÏÓÐÀµÓÚÄÔ¼¹ÒºÖÐNMDAÊÜÌ忹ÌåµÄ´æÔÚÀ´Ö¤Êµ¡£

    ÏÖÓеÄÖÎÁÆÖ¤¾Ý

    Ö÷ÒªµÄÖÎÁÆ·½°¸°üÀ¨Ö§³ÖÐÔÖÎÁÆ¡¢ÃâÒßÖÎÁÆ£¬Èç¹ûÓÐÖ×ÁöÔò½øÐÐÖ×ÁöÇгýÊõ¡£Ò»°ãÀ´Ëµ£¬Ò»ÏßµÄÃâÒßÖÎÁÆÓɸ߼ÁÁ¿Àà¹Ì´¼¡¢¾²×¢ÃâÒßÇòµ°°×(IVIg)¡¢Ñª½¬Öû»×é³É£¬²»Í¬µÄÒ½ÁÆ»ú¹¹»áÑ¡Ôñµ¥¶ÀʹÓá¢×éºÏʹÓûò˳ÐòʹÓÃÕ⼸ÖÖÖÎÁÆ¡£Æù½ñΪֹ£¬ÉÐÎÞÊý¾Ý֤ʵÆäËû·½·¨µÄÓÅÔ½ÐÔ¡£ÀûÍ×Îôµ¥¿¹ºÍ»·Á×õ£°·Í¨³£×÷Ϊ¶þÏßÖÎÁÆ£¬ÓÃÓÚµÚÒ»ÏßÖÎÁÆʧ°ÜµÄ»¼Õß¡£

    
        
            
                
                    Ò»Ïî´óÐ͹۲ìÐÔÑо¿ÄÉÈëÁË577Àý»¼Õߣ¬½á¹ûÏÔʾ£º
                
                    94%µÄ»¼Õß½ÓÊÜÁËÒ»ÏßÖÎÁÆ»òÖ×ÁöÇгý£¬ÆäÖÐÒ»°ë»¼ÕßÔÚ4ÖܺóÏÔÖø¸ÄÉÆ£¬¹²ÓÐ57%µÄ»¼Õß½ÓÊÜÒ»ÏßÖÎÁƺóûÓиÄÉÆ£¬¹Ê½ÓÊܶþÏßÒ©ÎïÖÎÁÆ¡£
                
                    78%µÄ»¼Õß½ÓÊÜÖÎÁƺó£¬24¸öÔÂʱ¸ÄÁ¼RankinÁ¿±íÆÀ·Ö≤2·Ö£¬¶øÔÚδ½ÓÊܶþÏßÖÎÁƵĻ¼ÕßÖÐÕâÒ»±ÈÀýΪ55%¡£
                
                    ×ÜÌå¶øÑÔ£¬81%µÄ»¼ÕßÔÚ24¸öÔÂʱÓÐÁ¼ºÃµÄÔ¤ºó£¬¶þÏßÃâÒßÁÆ·¨Ò²½µµÍÁ˸´·¢µÄ·çÏÕ¡£ÓëÁ¼ºÃ½á¾ÖÏà¹ØµÄÆäËûÒòËØ°üÀ¨Ö×ÁöÇå³ý£¨Èç¹û´æÔÚ£©¡¢²»ÐèÒª½øÈëICU¡¢Ö¢×´·¢×÷ºÍ½ÓÊÜÖÎÁƵÄʱ¼ä¼ä¸ô¸ü¶Ì¡£
                
                    ¹²ÓÐ45Àý»¼ÕßÓÐÒ»´Î»ò¶à´Î¸´·¢¡£
                
                    
                
                    ÆäËûСÐÍÑо¿·ÖÎöÁË¿¹NMDAÊÜÌåÄÔÑ׵ĶùͯºÍ³ÉÈË»¼ÕߵĽá¹û£¬²¢µÃ³ö½áÂÛ£¬ÈÏΪÔçÆÚÖÎÁƶÔÓÚ¸ÄÉÆÁÙ´²½á¹ûÊÇÖØÒªµÄ¡£ÉÐδÓпª·Å±êÇ©ÖÎÁÆÊÔÑéÀ´ÆÀ¹ÀÕâЩÖÎÁƵÄÁÆЧ£¬ËùÓÐÏÖÓеÄÖ¤¾Ý¶¼±»ÆÀ¶¨ÎªIV¼¶¡£
            
        
    


    Josep Dalmau½ÌÊڵĹ۵ã

    ¿¹NMDAÊÜÌåÄÔÑ×µÄÖÎÁÆÁ÷³ÌÉÐÎ޹淶»¯µÄ±ê×¼¡£ÎÒÃÇͨ³£Ê¹ÓÃIVIg 0.4 g/(kg·d)ÁªºÏ¼×ÆÃÄáÁú1g/d³ÖÐø5Ì죬×÷ΪһÏßÖÎÁÆ£¬ºóÐøÎÞ¼¤ËؼõÁ¿¡£

    Ä¿Ç°»¹Ã»ÓÐÊý¾ÝÖ§³ÖѪ½¬Öû»ÓÅÓÚIVIg£¬´ÓÃâÒßѧµÄ½Ç¶ÈÀ´¿´£¬¿¹ÌåÔÚÈ«ÉíºÍÄÔÄÚ¾ùÓкϳɣ¬Ñª½¬Öû»¿ÉÒÔÈ¥³ýÈ«ÉíµÄ¿¹Ì壬µ«²»ÄܸıäÄÔÄÚ·¢ÉúµÄ×ÔÉíÃâÒß¹ý³Ì¡£Õâ¾ÍÊÇΪʲô¶à´ï14%µÄ»¼ÕßѪÇ忹ÌåÒõÐÔ£¬µ«ÄÔ¼¹Òº¿¹ÌåÑôÐÔ¡£´ËÍ⣬ÔÚ×ÔÖ÷Éñ¾­¹¦Äܲ»Îȶ¨ºÍ¼«¶È¼¤¶¯µÄ»¼ÕßÖÐ×öÕâÏî²Ù×÷¿ÉÄܷdz£ÓÐÌôÕ½ÐÔ¡£

    Ò»ÏßÖÎÁƵķ´Ó¦Í¨³£ÔÚ10¡«15Ììºó½øÐÐÁÙ´²ÆÀ¼Û¡£¿¹ÌåµÎ¶ÈËäÈ»ÓÐÖúÓÚÕï¶Ï£¬µ«²»ÄÜÓÃÓÚÅжÏÖÎÁƵÄÁÆЧ¡£ÆäÖУ¬Ò»°ëÒÔÉϵĻ¼Õß½«¶ÔÒ»ÏßÖÎÁÆÎÞ·´Ó¦¶øÊÜÒæÓÚ¶þÏßÖÎÁÆ¡£¶þÏßÃâÒßÁÆ·¨Í¨³£ÓÉÀûÍ×Îôµ¥¿¹×é³É£¬¼ÁÁ¿¿ÉÒÔÑ¡ÔñÿÖÜ375 mg/m2£¬³ÖÐø4ÖÜ£¬²¢ÇÒ¾­³£Óë»·Á×õ£°·ÁªºÏÓÃÒ©£¬ÌرðÊdzÉÈË»¼Õߣ¬ºóÕßÓ÷¨Îª750 mg/m2ÿ¸öÔ£¬³ÖÐø4¡«6¸öÔ¡£

    ÏÖÔÚÎÒÏàÐÅ£¬ÎÒÃÇÕýÔÚ³¯×ŸüÈ«ÃæµÄÃâÒßÖÎÁƵķ½ÏòÂõ½ø£¬°üÀ¨Í¬Ê±¸øÓèÀûÍ×Îôµ¥¿¹£¬IVIg»òѪ½¬Öû»£¬ÒÔ¼°¼×ÆÃÄáÁú¡£ÔÚ°ÍÈûÂÞÄÇ´óѧҽԺÕïËù£¬ÎÒÃÇ»áʹÓÃÕâÖÖ×ÛºÏÐÔÃâÒßÖÎÁƵÄÒ»²¿·Ö£¬°üÀ¨ÀûÍ×Îôµ¥¿¹ÒÔ¼°Ñª½¬Öû»ºÍIVIg¡£ÔÚ±¾·½°¸ÖУ¬10ÌìÄÚ¸øÓ軼Õß6´ÎѪ½¬Öû»£¬Óð׵°°×²¹³äµ°°×ÖʵÄËðʧ£¬Æä´ÎÊÇIVIg¡£Ä¿Ç°Éв»Çå³þѪ½¬Öû»ºÍIVIg×éºÏʹÓÃÊÇ·ñÓÅÓÚµ¥Ó㬵«ÎÒÈÏΪ£¬ÔçÆÚ»ý¼«µÄÖÎÁÆ£¬¶ÔÓڸıäÕâÖÖ¿ÉÄÜÖÂÃüµÄ¼²²¡½ø³Ì²¢·ÀÖ¹¸´·¢ÊǺÜÖØÒªµÄ¡£

    Èç¹û»¼ÕßÓи´·¢£¬Í¨³£»á¿¼ÂÇÖظ´×î³õÓÐЧµÄÖÎÁÆ·½°¸£¬Èç¹ûÒÔǰûÓиø¹ý¶þÏßÖÎÁÆ£¬ÔòÉ϶þÏß¡£Ä¿Ç°ÎÒÃDz»Ê¹Ó*************************¹·ÓËáõ¥ºÍÁòßòàÑßÊ£¬ÊÂʵÉÏ£¬Ã»ÓÐÑо¿±íÃ÷ÕâЩҩÎïÔÚ¼±ÐÔÆÚ»òÔ¤·À¸´·¢ÖÐÓÐЧ£¬ÉÐÐè¶àÖÐÐÄÇ°Õ°ÐÔÑо¿À´ÆÀ¹ÀÕâЩÃâÒßÖÎÁƵÄÁÆЧ¡£

    ÍƼöÔĶÁ£º

    Ò½Âöͨ±àÒë×Ô£ºLuca Bartolini. Practice Current: How do you treat anti-NMDA receptor encephalitis?[J]. Neurol Clin Pract 2016;6;69-72.
·ÖÏí:

ÓÞÓÞѧ԰ÊôÓÚ´¿Ñ§Êõ¡¢·Ç¾­ÓªÐÔרҵÍøÕ¾£¬ÎÞÈκÎÉÌÒµÐÔÖÊ£¬´ó¼Ò³öÓÚѧϰºÍ¿ÆÑÐÄ¿µÄ½øÐн»Á÷ÌÖÂÛ¡£

ÈçÓÐÉæÇÖ·¸Öø×÷ȨÈ˵İæȨµÈÐÅÏ¢£¬Ç뼰ʱÀ´ÐŸæÖª£¬ÎÒÃǽ«Á¢¿Ì´ÓÍøÕ¾ÉÏɾ³ý£¬²¢ÏòËùÓгְæȨÕßÖÂ×îÉîǸÒ⣬лл¡£